Biblio Discovery — Demo Discovery Service

11 hasil untuk "T. Decroo"

Menampilkan 1–11 · 0,64 detik · RSS

  1. Artikel Jurnal

    Impact of bedaquiline resistance probability on treatment decision for rifampicin-resistant TB

    T.P.H. Trang; R. Kessels; T. Decroo dkk.

    IJTLD Open, Vol. 1 No. 9 · 2024 · Inggris · DOAJ Scopus

    BACKGROUND: Accurate diagnosis of bedaquiline (BDQ) resistance remains challenging. A Bayesian approach expresses this uncertainty as a probability of BDQ resistance (prBDQR) with a 95% credible interval. We investigated how prBDQ R information influences BDQ prescribing decisions. METHOD: We…

  2. Artikel Jurnal

    “If your CD4 count lowers, that is when you are similar to a person that is non-existent” A qualitative exploration of perceptions around advanced HIV disease in South Africa

    TP Pita; S. Misra; T. Madonsela dkk.

    BMC Public Health, Vol. 25 No. 1 · 2025 · Inggris · DOAJ Scopus

    Abstract Background Despite widespread availability and differentiated delivery of antiretroviral treatment (ART), advanced HIV disease (AHD) remains prevalent, with high mortality risk. In South Africa, we assessed perceptions about the meaning of AHD and social and behavioural factors influencing…

  3. Artikel Jurnal

    The time is now: making the case for compassionate use/pre-approval access to new TB drugs

    A. Reuter; J. Stillo; S.S. Thi dkk.

    IJTLD Open, Vol. 2 No. 12 · 2025 · Inggris · DOAJ Scopus

    SUMMARY: Although the majority of people with multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB) can now be successfully treated with all-oral shorter regimens, rising rates of resistance to the components in these regimens are a growing global challenge. The drug development pipeline for TB…

  4. Artikel Jurnal

    Using linezolid as a substitute for the injectable in case of ototoxicity is safer and as effective as all-oral treatment for rifampicin-resistant TB

    M.B. Souleymane; T. Decroo; A. Soumana dkk.

    IJTLD Open, Vol. 2 No. 8 · 2025 · Inggris · DOAJ Scopus

    BACKGROUND: WHO recommends all-oral bedaquiline (BDQ) and linezolid (LZD)-containing regimens for rifampicin-resistant TB (RR-TB). In Niger, high cure rates were achieved using an adaptive short treatment regimen (aSTR) with a second-line injectable drug (SLID) and LZD, where LZD replaced the SLID…

  5. Artikel Jurnal

    Fifteen years of rifampicin-resistant TB control in Niger: high countrywide treatment uptake and success

    I. Maman Lawan; T. Decroo; M.B. Souleymane dkk.

    IJTLD Open, Vol. 3 No. 1 · 2026 · Inggris · DOAJ Scopus

    BACKGROUND: Few rifampicin-resistant TB (RR-TB) studies show pre-treatment outcomes and definitive treatment outcomes (accounting for RR-TB re-treatment). Our Niger countrywide study covered 15 years to show the trend of RR-TB diagnoses, time-to-treatment initiation, and pre-and on-treatment…

  6. Artikel Jurnal

    High-dose amikacin in the first week of all-oral rifampicin-resistant TB treatment is safe: a single-arm trial

    J. Snobre; J. Gasana; T. Decroo dkk.

    IJTLD Open, Vol. 2 No. 11 · 2025 · Inggris · DOAJ Scopus

    BACKGROUND: Effective rifampicin-resistant TB (RR-TB) treatment should prevent resistance development. Bedaquiline is central to all-oral regimens, but it is threatened by rising resistance, possibly due to its delayed bactericidal effect. We evaluated the safety of strengthening the 1st week of…

  7. Artikel Jurnal

    Clinical best practices for caring for people with expanded resistance to newer TB drugs

    T. Nkomo; Z. Udwadia; D. Vambe dkk.

    IJTLD Open, Vol. 2 No. 6 · 2025 · Inggris · DOAJ Scopus

    BACKGROUND: Strains of Mycobacterium tuberculosis with resistance to the new and repurposed drugs included in the all-oral shorter TB regimens recommended by WHO for the treatment of multidrug-resistant/rifampicin-resistant TB (MDR/RR-TB) are becoming increasingly common globally. When strains of…